ABOUT GRAVITAS
company
Gravitas is a virtual pharmaceutical company focused on the development of a single antifungal agent, GR-2397. GR-2397 is the first of a new class of small molecule antifungal agents being developed for the treatment of serious fungal infections.
Our mission is to achieve one of the most important advances in the treatment of severe fungal infections in decades.
team
Gravitas’ leadership has extensive experience building biopharmaceutical companies and developing novel antifungal therapeutics. In its current virtual form, the Gravitas team is largely comprised of consultants and advisors. These individuals provide functional area expertise for clinical development, medical microbiology, regulatory affairs, clinical operations, CMC and project management, non-clinical toxicology, PK/ADME, and commercial.
Gravitas is led by Tom Smart, MBA, CEO, board chair and a founder. Mr. Smart, a former CEO and board chair of AnaptysBio (NASDAQ: ANAB), is a biopharma executive, and entrepreneur with 20 years’ experience as CEO, CBO, SVP, chairman and executive chair. Under Mr. Smart’s leadership, AnaptysBio initiated the drug discovery and development program of the now FDA and EU approved programmed death receptor-1 (PD-1)-blocking antibody, JEMPERLI (dostarlimab-gxly). BS, Cornell University; MBA, University of Chicago Booth School of Business.
Gravitas’ primary medical advisor is Oliver Cornely, MD, FACP, FIDSA, FAAM, FECMM. Dr. Cornely is Professor and Chair of Translational Research at the CECAD Institute of the University of Cologne. He is also Scientific Director of the Center for Clinical Trials, and Professor of Internal Medicine and Consultant in Infectious Diseases at the Department I of Internal Medicine, at the University Hospital of Cologne. MD, University Hospital at Albertus Magnus University, Cologne.
